FrancophonIA/ELRC3.0 huggingface dataset:
English: Ivabradine Anpharm with food and drink Avoid grapefruit juice during treatment with Ivabradine Anpharm.
Slovenian: Zdravilo Ivabradine Anpharm skupaj s hrano in pijačo Med zdravljenjem z zdravilom Ivabradine Anpharm se izogibajte uživanju grenivkinega soka.
English: The study demonstrated a clinically and statistically significant relative risk reduction of 18% in the rate of the primary composite endpoint of cardiovascular mortality and hospitalisation for worsening heart failure (hazard ratio: 0.82, 95%CI [0.75;0.90] - p<0.0001) apparent within 3 months of initiation of treatment.
Slovenian: Študija je dokazala klinično in statistično značilno relativno zmanjšanje tveganja za 18 % za primarni končni izid, sestavljen iz srčno-žilne umrljivosti in hospitalizacije zaradi poslabšanja srčnega popuščanja (razmerje tveganja: 0,82, 95 % interval zaupanja [0,75;0,90] - p<0,0001), vidnega po 3
English: A randomised, double blind, placebo controlled study was performed in 116 paediatric patients (17 aged [6-12[months, 36 aged [1-3[ years and 63 aged [3-18[ years) with CHF and dilated cardiomyopathy (DCM) on top of optimal background treatment.
Slovenian: Pediatrična populacija Randomizirana, dvojno slepa, s placebom nadzorovana študija je vključevala 116 pediatričnih bolnikov (17 bolnikov, starih [6-12[ mesecev, 36 bolnikov, starih [1-3[ leta in 63 bolnikov, starih [3-18[ let) s kroničnim srčnim popuščanjem in dilatirano kardiomiopatijo (DKM), ki so prejemali ivabradin poleg optimalnega osnovnega zdravljenja.
English: Grapefruit juice: ivabradine exposure was increased by 2-fold following the co-administration with grapefruit juice.
Slovenian: Sočasno jemanje ni priporočljivo Grenivkin sok: izpostavljenost ivabradinu se je 2-kratno povečala po sočasnem jemanju z grenivkinim sokom.
English: In a 97-patient randomised placebo-controlled study, the data collected during specific ophthalmologic investigations, aiming at documenting the function of the cone and rod systems and the ascending visual pathway (i.e. electroretinogram, static and kinetic visual fields, colour vision, visual acuity), in patients treated with ivabradine for chronic stable angina pectoris over 3 years, did not show any retinal toxicity.
Slovenian: Podatki, ki so bili v randomizirani, s placebom nadzorovani študiji s 97 bolniki zbrani med specifičnimi oftalmološkimi preiskavami, namenjenimi dokumentiranju delovanja paličic in čepkov ter ascendentnih vidnih poti (kot so elektrokardiogram, statična in kinetična perimetrija, preiskava barvnega vida in ostrine vida), niso pokazali toksičnih učinkov na mrežnico pri bolnikih, ki so 3 leta prejemali ivabradin za zdravljenje kronične stabilne angine pektoris.
English: In a post-hoc subgroup of patients with symptomatic angina at randomisation (n=1507), no safety signal was identified regarding cardiovascular death, hospitalization for acute MI or heart failure (ivabradine 12.0% versus placebo 15.5%, p=0.05).
Slovenian: V post-hoc podskupini bolnikov, ki so ob naključni razvrstitvi imeli simptomatsko angino pektoris (n = 1507), niso zaznali signala o varnosti glede srčno-žilne umrljivosti in hospitalizacije zaradi akutnega miokardnega infarkta ali srčnega popuščanja (ivabradin 12,0 %, placebo 15,5 %, p = 0,05).
English: 5 How to store Ivabradine Anpharm Contents of the pack and other information
Slovenian: Shranjevanje zdravila Ivabradine Anpharm Vsebina pakiranja in dodatne informacije
English: Do not use this medicine after the expiry date which is stated on the carton and blister after ‘EXP'.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
English: ElderlyIn patients aged 75 years or more, a lower starting dose should be considered (2.5 mg twice daily i.e. one half 5 mg tablet twice daily) before up-titration if necessary.
Slovenian: Pri bolnikih, starih 75 ali več let, morate razmisliti o manjšem začetnem odmerku (2,5 mg dvakrat na dan, to je eno polovico 5-mg tablete dvakrat na dan), ki ga lahko nato povečate, če je potrebno.
English: PK/PD relationship analysis has shown that heart rate decreases almost linearly with increasing ivabradine and S 18982 plasma concentrations for doses of up to 15-20 mg twice daily.
Slovenian: Farmakokinetično/farmakodinamično (PK/PD) razmerje Analiza razmerja med farmakokinetiko in farmakodinamiko je pokazala, da se srčna frekvenca znižuje skoraj linearno s povečevanjem koncentracije ivabradina in S 18982 v plazmi ob odmerkih do 15 do 20 mg dvakrat na dan.
English: Ivabradine Anpharm 7.5 mg film-coated tablets EU/1/15/1041/008-014
Slovenian: Ivabradine Anpharm 7,5 mg filmsko obložene tablete EU/1/15/1041/008-014
English: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Slovenian: Druga zdravila in zdravilo Ivabradine Anpharm Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
English: In a 889-patients randomised placebo-controlled study, ivabradine given on top of atenolol 50 mg o.d. showed additional efficacy on all ETT parameters at the trough of drug activity (12 hours after oral intake).
Slovenian: V randomizirani, s placebom nadzorovani študiji pri 889 bolnikih, ki so ivabradin jemali poleg atenolola 50 mg enkrat na dan, je ivabradin dodatno deloval na vse parametre obremenitvenega testa v času najmanjšega učinka (12 ur po peroralnem jemanju).
English: In some cases (e.g. if you are elderly), your doctor may prescribe half the dose i.e., one half 5 mg tablet of Ivabradine Anpharm 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the evening.
Slovenian: Nekaterim bolnikom (na primer, če ste starejši) lahko zdravnik predpiše polovični odmerek, se pravi eno polovico 5 mg tablete (kar ustreza 2,5 mg ivabradina) zjutraj in eno polovico 5 mg tablete zvečer.
English: The starting dose should not exceed one tablet of Ivabradine Anpharm 5 mg twice daily.
Slovenian: Začetni odmerek ne sme presegati ene tablete zdravila Ivabradine Anpharm 5 mg dvakrat na dan.
English: There was an improvement in NYHA class in 37.7% of ivabradine patients versus 25.0% in the placebo group.
Slovenian: Funkcionalni razred NYHA se je izboljšal pri 37,7 % bolnikov, ki so prejemali ivabradin, v primerjavi s 25,0 % bolnikov iz skupine, ki je prejemala placebo.
English: - The other ingredients in the tablet core are: lactose monohydrate, magnesium stearate (E 470 B), maize starch, maltodextrin, colloidal anhydrous silica (E 551), and in the tablet coating: hypromellose (E 464), titanium dioxide (E 171), macrogol 6000, glycerol (E 422), magnesium stearate (E 470 B), yellow iron oxide (E 172), red iron oxide (E 172).
Slovenian: - Pomožne snovi so: laktoza monohidrat, magnezijev stearat (E 470 B), koruzni škrob, maltodekstrin, brezvodni koloidni silicijev dioksid (E 551) v jedru tablete in hipromeloza (E 464), titanov dioksid (E 171), makrogol 6000, glicerol (E 422), magnezijev stearat (E 470 B), rumeni železov oksid (E 172), rdeči železov oksid (E 172) v oblogi tablete.
English: A 20% heart rate reduction, without bradycardia, was achieved by 69.9% of patients in the ivabradine group versus 12.2% in the placebo group during the titration period of 2 to 8 weeks (Odds Ratio: E = 17.24, 95% CI [5.91 ; 50.30]).
Slovenian: Znižanje srčne frekvence za 20 % brez bradikardije so dosegli pri 69,9 % bolnikov iz skupine, ki je prejemala ivabradin, v primerjavi z znižanjem za 12,2 % v skupini, ki je prejemala placebo med obdobjem povečevanja odmerka, ki je trajalo 2-8 tednov (razmerje obetov: E = 17,24, 95% IZ
English: ECG prolonged QT interval * Frequency calculated from clinical trials for adverse events detected from spontaneous report
Slovenian: Preiskave občasni povečanje kreatinina v krvi podaljšanje intervala QT na EKG *Pogostnost neželenih učinkov iz spontanega poročanja je izračunana na podlagi podatkov iz kliničnih študij
English: The main efficacy criterion was the composite of cardiovascular death or non-fatal MI.
Slovenian: Poglavitno merilo učinkovitosti je bil sestavljen izid srčno-žilne umrljivosti ali neusodnega miokardnega infarkta.
English: Analysis of heart rate reduction with doses up to 20 mg twice daily indicates a trend towards a plateau effect which is consistent with a reduced risk of severe bradycardia below 40 bpm (see section 4.8).
Slovenian: Analiza znižanja srčne frekvence ob odmerkih do 20 mg dvakrat na dan kaže na težnjo, da učinek doseže plato, kar je skladno z zmanjšanim tveganjem hude bradikardije pod
English: Contraindication of concomitant use
Slovenian: Kontraindikacije za sočasno jemanje
English: The following adverse reactions have been reported during clinical trials and are ranked using the following frequency: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Slovenian: Tabelarični seznam neželenih učinkov V kliničnih študijah so poročali o naslednjih neželenih učinkih, ki so razvrščeni po naslednji pogostnosti: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki
English: Ivabradine did not show additional efficacy on secondary endpoints of ETT parameters at the trough of drug activity while an additional efficacy was shown at peak (3-4 hours after oral ivabradine intake).
Slovenian: Ivabradin ni pokazal dodatne učinkovitosti na sekundarne končne izide parametrov obremenitvenega testiranja v času najmanjšega učinka, medtem ko so v času največjega učinka (3-4 ure po peroralnem jemanju) dodatno učinkovitost zasledili.
English: In a pooled analysis of all the Phase II/III double blind controlled clinical trials with a duration of at least 3 months including more than 40,000 patients, the incidence of atrial fibrillation was 4.86% in ivabradine treated patients compared to 4.08% in controls, corresponding to a hazard ratio of 1.26, 95% CI [1.15-1.39].
Slovenian: ali III. faze, ki so trajale najmanj 3 mesece in v katere je bilo vključenih več kot 40.000 bolnikov, je bila pojavnost atrijske fibrilacije 4,86% pri bolnikih, ki so jemali ivabradin v primerjavi s 4,08% pojavnostjo v kontrolni skupini, kar ustreza razmerju tveganja 1,26, 95% IZ [1,15-1,39].
English: Do not take Ivabradine Anpharm - if you are allergic to ivabradine or any of the other ingredients of this medicine (listed in section
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Ivabradine Anpharm Ne jemljite zdravila Ivabradine Anpharm - če ste alergični na ivabradin ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
English: - Elderly: no pharmacokinetic differences (AUC and Cmax) have been observed between elderly (≥ 65 years) or very elderly patients (≥ 75 years) and the overall population (see section 4.2).
Slovenian: Posebne skupine bolnikov - Starejši: med starejšimi (≥ 65 let) ali najstarejšimi (≥ 75 let) bolniki in celotno populacijo niso opazili razlik v farmakokinetiki (površini pod krivuljo (AUC) ter največji koncentraciji v plazmi)
English: Therefore, ivabradine is contraindicated during breast-feeding (see section 4.3).
Slovenian: Ivabradin je torej kontraindiciran med dojenjem (glejte poglavje 4.3).
English: Do not take Ivabradine Anpharm if you are able to become pregnant unless you use reliable contraceptive measures (see “Do not take Ivabradine Anpharm”).
Slovenian: Če ste ženska v rodni dobi ne smete jemati zdravila Ivabradine Anpharm, razen če uporabljate zanesljive kontracepcijske metode (glejte “Ne jemljite zdravila Ivabradine Anpharm”).
English: The absence of pharmacokinetic difference between the 2 formulations was shown in an openlabel randomised two-period cross-over study in 24 adult healthy volunteers.
Slovenian: Odprta randomizirana navzkrižna študija z dvema periodama, v kateri je sodelovalo 24 odraslih zdravih prostovoljcev, je pokazala odsotnost farmakokinetičnih razlik med omenjenima dvema oblikama.
English: Do not take Ivabradine Anpharm if you are pregnant or are planning to have a baby (see “Do not take Ivabradine Anpharm”).
Slovenian: Nosečnost in dojenje Ne jemljite zdravila Ivabradine Anpharm, če ste noseči ali če načrtujete nosečnost (glejte “Ne jemljite zdravila Ivabradine Anpharm”).
English: The concomitant use of potent CYP3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone is contraindicated (see section 4.3).
Slovenian: Sočasno jemanje močnih zaviralcev citokroma P450 3A4, kot so azolski antimikotiki (ketokonazol, itrakonazol), makrolidnimi antibiotiki (klaritromicin, eritromicin peroralno, josamicin, telitromicin), zaviralci proteaze virusa HIV (nelfinavir, ritonavir) in nefazodon, je kontraindicirano (glejte poglavje 4.3).
English: Ivabradine was shown not to influence the metabolism and plasma concentrations of other CYP3A4 substrates (mild, moderate and strong inhibitors).
Slovenian: Dokazali so, da ivabradin ne vpliva na presnovo drugih substratov citokroma P450 3A4 in njihove koncentracije v plazmi (blagih, zmernih in močnih zaviralcev).
English: Musculoskeletal and connective tissue disorders
Slovenian: Bolezni mišično-skeletnega sistema in vezivnega tkiva občasni mišični spazmi
English: Treatment must be discontinued if heart rate remains below 50 bpm or symptoms of bradycardia persist (see section 4.4).
Slovenian: Zdravljenje morate prekiniti, če srčna frekvenca ostane pod 50 utripov na minuto ali simptomi bradikardije vztrajajo (glejte poglavje 4.4).
English: If heart rate increases persistently above 60 beats per minute at rest, the dose can be up titrated to the next upper dose in patients receiving 2.5 mg twice daily or 5 mg twice daily.
Slovenian: Če se srčna frekvenca med mirovanjem vztrajno povečuje nad 60 utripov na minuto, lahko odmerek titrirate navzgor do naslednjega večjega odmerka pri bolnikih, ki jemljejo 2,5 mg dvakrat na dan ali 5 mg dvakrat na dan.
English: Ivabradine has low affinity for CYP3A4, shows no clinically relevant CYP3A4 induction or inhibition and is therefore unlikely to modify CYP3A4 substrate metabolism or plasma concentrations.
Slovenian: Ivabradin ima majhno afiniteto za citokrom P450 3A4, ki ga ne spodbuja ali zavira klinično pomembno, zato ni verjetno, da bi vplival na presnovo substratov citokroma P450 3A4 ali njihovo koncentracijo v plazmi.
English: Ivabradine Anpharm (ivabradine) is a heart medicine used to treat: - Symptomatic stable angina pectoris (which causes chest pain) in adult patients whose heart rate is over or equal to 70 beats per minute.
Slovenian: Kaj je zdravilo Ivabradine Anpharm in za kaj ga uporabljamo Ivabradine Anpharm (ivabradin) je zdravilo za srce, namenjeno za zdravljenje: - simptomatske stabilne angine pektoris (bolezen, ki povzroča bolečine v prsih) pri odraslih bolnikih, ki imajo srčno frekvenco višjo ali enako 70 utripom na minuto.
English: Sick sinus syndrome
Slovenian: - sindrom bolnega sinusnega vozla - sinoatrijski blok
English: INFORMATION IN BRAILLE Ivabradine Anpharm 5 mg
Slovenian: PODATKI V BRAILLOVI PISAVI Ivabradine Anpharm 5 mg
English: Mean LVEF increased from 31.8% to 45.3% at M012 in ivabradine group versus 35.4% to 42.3% in the placebo group.
Slovenian: Pri bolnikih iz skupine, ki je prejemala ivabradin, se je povprečni iztisni delež levega prekata v 12. mesecu zdravljenja povečal z 31, 8 % na 45,3 % v primerjavi s 35,4 % na 42,3 % v skupini, ki je prejemala placebo.
English: Palpitations and cardiac extra beats, feeling sick (nausea), constipation, diarrhoea, abdominal pain, spinning sensation (vertigo), difficulty breathing (dyspnoea), muscle spasms, changes in laboratory parameters : high blood levels of uric acid, an excess of eosinophils (a type of white blood cell) and elevated creatinine in blood (a breakdown product of muscle), skin rash, angioedema (such as swollen face, tongue or throat, difficulty in breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of weakness, abnormal ECG heart tracing, double vision, impaired vision.
Slovenian: Palpitacije in dodatni srčni utripi, občutek slabosti (navzea), zaprtje, driska, bolečina v trebuhu, občutek vrtoglavosti (vertigo), oteženo dihanje (dispneja), mišični spazmi (krči), spremembe laboratorijskih parametrov: visoke vrednosti sečne kisline v krvi, preveliko število eozinofilcev (vrsta belih krvnih celic) in povečanje kreatinina v krvi (razgradni produkt mišic), kožni izpuščaj,
English: Potassium-depleting diuretics (thiazide diuretics and loop diuretics): hypokalemia can increase the risk of arrhythmia.
Slovenian: Sočasno jemanje, ki zahteva posebno previdnost Diuretiki, ki povzročijo izgubo kalija (tiazidni diuretiki in diuretiki zanke): hipokaliemija lahko poveča tveganje za aritmijo.
English: INFORMATION IN BRAILLE Ivabradine Anpharm 7.5 mg
Slovenian: PODATKI V BRAILLOVI PISAVI Ivabradine Anpharm 7,5 mg
English: In the subgroup of patients with HR ≥ 75 bpm and on the recommended target dose of beta-blocker, no statistically significant benefit was observed on the primary composite endpoint (hazard ratio: 0.97, 95%CI [0.74;1.28]) and other secondary endpoints, including hospitalisation for worsening heart failure (hazard ratio: 0.79, 95% CI [0.56;1.10]) or death from heart failure (hazard ratio: 0.69, 95% CI [0.31;1.53]).
Slovenian: V podskupini bolnikov s srčno frekvenco ≥ 75 utripov na minuto zdravljenih s priporočenim ciljnim odmerkom antagonista adrenergičnih receptorjev beta, ni bilo opažene statistično značilne koristi glede primarnega sestavljenega končnega izida (razmerje tveganja: 0,97, 95 % interval zaupanja [0,74; 1,28]) in drugih sekundarnih končnih izidov, vključno s hospitalizacijo zaradi poslabšanja srčnega popuščanja (razmerje tveganja: 0,79, 95 % interval zaupanja [0,56; 1,10]) ali umrljivosti zaradi srčnega popuščanja (razmerje tveganja: 0,69, 95 % [0,31; 1,53]).
English: In particular, the additional benefit over 5 mg twice daily was established in a reference-controlled study versus atenolol: total exercise duration at trough was increased by about 1 minute after one month of treatment with 5 mg twice daily and further improved by almost 25 seconds after an additional 3-month period with forced titration to 7.5 mg twice daily.
Slovenian: 1 minuto po enem mesecu zdravljenja z odmerkom 5 mg dvakrat na dan in še nadalje izboljšalo za skoraj 25 sekund po dodatnem 3-mesečnem obdobju z obveznim titriranjem na 7,5 mg dvakrat na dan.
English: It is recommended to regularly clinically monitor ivabradine treated patients for the occurrence of atrial fibrillation (sustained or paroxysmal), which should also include ECG monitoring if clinically indicated (e.g. in case of exacerbated angina, palpitations, irregular pulse).
Slovenian: Atrijska fibrilacija je bolj pogosta pri bolnikih, ki sočasno jemljejo amjodaron in močne antiaritmike skupine I. Pri bolnikih, ki jemljejo ivabradin, je priporočljivo redno klinično spremljanje možnosti pojava atrijske fibrilacije (vztrajne ali paroksizmalne), kar mora vključevati tudi EKG, če je klinično indiciran (na primer pri bolnikih s poslabšanjem angine pektoris, palpitacijami, nerednim utripom).
English: A large dose of Ivabradine Anpharm could make you feel breathless or tired because your heart slows down too much.
Slovenian: Če ste vzeli večji odmerek zdravila Ivabradine Anpharm, kot bi smeli Velik odmerek zdravila Ivabradine Anpharm bi lahko povzročil zasoplost ali utrujenost, ker preveč upočasni srce.
English: The SHIFT study was a large multicentre, international, randomised double-blind placebo controlled outcome trial conducted in 6505 adult patients with stable chronic CHF (for ≥ 4 weeks), NYHA class II to IV, with a reduced left ventricular ejection fraction (LVEF ≤ 35%) and a resting heart rate ≥ 70 bpm.
Slovenian: Študija SHIFT je bila obsežno multicentrično, mednarodno, randomizirano, dvojno slepo, s placebom nadzorovano preskušanje izida, ki je zajelo 6505 odraslih bolnikov s stabilnim kroničnim srčnim popuščanjem (≥ 4 tedne) II.
English: The efficacy of 5 and 7.5 mg twice daily was consistent across studies on exercise test parameters (total exercise duration, time to limiting angina, time to angina onset and time to 1 mm ST segment depression) and was associated with a decrease of about 70% in the rate of angina attacks.
Slovenian: (skupnega trajanja vadbe, časa do omejujoče angine, časa do nastopa angine in časa do 1-mm depresije segmenta ST) je bila dosledna v vseh študijah ter povezana z zmanjšanjem števila anginoznih napadov za približno 70 %.
English: MARKETING AUTHORISATION NUMBER(S) Ivabradine Anpharm 5 mg film-coated tablets EU/1/15/1041/001-007
Slovenian: Ivabradine Anpharm 5 mg filmsko obložene tablete EU/1/15/1041/001-007
English: Servier Italia S.p.A. Tel: +39 06 669081
Slovenian: Tel: +39 06 669081
English: If you forget to take Ivabradine Anpharm:
Slovenian: Če ste pozabili vzeti zdravilo Ivabradine Anpharm
English: The usual recommended starting dose is one tablet of Ivabradine Anpharm 5 mg twice daily increasing if necessary to one tablet of Ivabradine Anpharm 7.5 mg twice daily.
Slovenian: Če se zdravite zaradi kroničnega srčnega popuščanja Običajen priporočljiv začetni odmerek je ena tableta zdravila Ivabradine Anpharm 5 mg dvakrat na dan, kar lahko povečate na eno tableto zdravila Ivabradine Anpharm 7,5 mg dvakrat na dan, če je potrebno.
English: The mean ivabradine doses allowing to achieve a 20% HRR were 0.13 ± 0.04 mg/kg bid, 0.10 ± 0.04 mg/kg bid and 4.1 ± 2.2 mg bid in the age subsets [1-3[ years, [3-18[ years and <40 kg and [3-18[
Slovenian: Povprečni odmerki ivabradina, s katerimi so dosegli 20% znižanje srčne frekvence, so bili pri podskupini bolnikov, starih [1-3[ leta, 0,13 ± 0,04 mg/kg dvakrat na dan, pri bolnikih, starih [3-18[ let, ki so tehtali manj kot 40 kg, 0,10 ± 0,04 mg/kg dvakrat na dan ter pri bolnikih, starih [3-18[ let, ki so tehtali 40 kg ali več, 4,1 ± 2,2 mg dvakrat na dan.
English: They particularly occur within the first 2 to 3 months of treatment initiation.
Slovenian: 2 do 3 mesecih zdravljenja.
English: - Non cardiovascular QT prolonging medicinal products (e.g. pimozide, ziprasidone, sertindole,
Slovenian: ibutilid, amjodaron) - nesrčno-žilna zdravila, ki podaljšujejo interval QT (na primer pimozid, ziprazidon, sertindol,
English: Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm.
Slovenian: Ivabradin je indiciran za simptomatsko zdravljenje kronične stabilne angine pektoris pri odraslih s koronarno arterijsko boleznijo z normalnim sinusnim ritmom in srčno frekvenco ≥ 70 utripov na minuto.
English: - if your resting heart rate before treatment is too slow (below 70 beats per minute); - if you are suffering from cardiogenic shock (a heart condition treated in hospital); - if you suffer from a heart rhythm disorder; - if you are having a heart attack; - if you suffer from very low blood pressure; - if you suffer from unstable angina (a severe form in which chest pain occurs very frequently and with or without exertion); - if you have heart failure which has recently become worse; - if your heartbeat is exclusively imposed by your pacemaker; - if you suffer from severe liver problems; - if you are already taking medicines for the treatment of fungal infections (such as ketoconazole,
Slovenian: - če imate kardiogeni šok (bolezen srca, ki zahteva zdravljenje v bolnišnici); - če imate motnje srčnega ritma; - če imate miokardni infarkt; - če imate zelo nizek krvni tlak; - če imate nestabilno angino pektoris (hudo obliko, pri kateri se bolečine v prsih pojavljajo zelo pogosto, med naporom ali brez njega);